Canada · Delayed Price · Currency is CAD Theseus Pharmaceuticals Statistics
Total Valuation
TSXV:NKG has a market cap or net worth of CAD 63.61 million. The enterprise value is 60.33 million.
| Market Cap | 63.61M |
| Enterprise Value | 60.33M |
Important Dates
The next estimated earnings date is Tuesday, August 26, 2025.
| Earnings Date | Aug 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:NKG has 424.09 million shares outstanding. The number of shares has increased by 14.82% in one year.
| Current Share Class | 424.09M |
| Shares Outstanding | 424.09M |
| Shares Change (YoY) | +14.82% |
| Shares Change (QoQ) | +5.43% |
| Owned by Insiders (%) | 37.60% |
| Owned by Institutions (%) | 6.23% |
| Float | 264.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.68 |
| P/TBV Ratio | 3.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.02 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.83 |
Financial Position
The company has a current ratio of 5.51
| Current Ratio | 5.51 |
| Quick Ratio | 5.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.90% and return on invested capital (ROIC) is -32.82%.
| Return on Equity (ROE) | -56.90% |
| Return on Assets (ROA) | -31.98% |
| Return on Invested Capital (ROIC) | -32.82% |
| Return on Capital Employed (ROCE) | -80.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -15.00M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.82% in the last 52 weeks. The beta is 0.78, so TSXV:NKG's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -50.82% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 0.25 |
| Relative Strength Index (RSI) | 40.94 |
| Average Volume (20 Days) | 167,050 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -93,549 |
| Operating Income | -13.84M |
| Pretax Income | -15.00M |
| Net Income | -15.00M |
| EBITDA | -13.78M |
| EBIT | -13.84M |
| Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 3.29 million in cash and n/a in debt, giving a net cash position of 3.29 million or 0.01 per share.
| Cash & Cash Equivalents | 3.29M |
| Total Debt | n/a |
| Net Cash | 3.29M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 17.27M |
| Book Value Per Share | 0.05 |
| Working Capital | 2.86M |
Cash Flow
In the last 12 months, operating cash flow was -11.98 million and capital expenditures -505,347, giving a free cash flow of -12.48 million.
| Operating Cash Flow | -11.98M |
| Capital Expenditures | -505,347 |
| Free Cash Flow | -12.48M |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSXV:NKG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.82% |
| Shareholder Yield | n/a |
| Earnings Yield | -23.58% |
| FCF Yield | -19.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 8, 2019. It was a reverse split with a ratio of 0.6666666.
| Last Split Date | Feb 8, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.6666666 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |